Search
Nabilone
go.drugbank.com/drugs/DB00486ApprovedInvestigationalactive as Δ⁹-THC. … It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics.
L-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalDL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine
Pepsin
go.drugbank.com/drugs/DB13198ApprovedWithdrawnInterestingly, it has been used as a marker for laryngopharyngeal reflux (LPR), which is a common illness of otolaryngology (ear, nose and throat specialist) visits [A32604]. … Many causes of pancreatic insufficiency require that enzyme replacement therapy is started, including cystic fibrosis, pancreatic cancer, acute and chronic pancreatitis, as well as pancreatic surgery [
Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalPalifermin was granted FDA approval on 15 December 2004.[L17933]
Xenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigationalLung MRIs are challenging due to the low proton density of this tissue, as well as the presence of artifacts due to respiration and cardiovascular pulsation movement and air–tissue interfaces. … [A255178] Xe-129 has a lower cost, and adverse effects are normally resolved shortly after administration.
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawn[A32643] It was developed by McNeil Pharmaceutical and approved by Health Canada on December 31, 1992. This medication was later discontinued from the market in 1998.[L1113] … [L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967. It was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202037] It was first introduced as an antiepileptic agent in the United Kingdom in 1989 and was used extensively until 1997, when an association with vision loss became apparent. … Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active.
Products: SABRIL 500MG TABLETVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalIt was first described in 1998 at the Pierre Fabre research center in France. … In 2009, vinflunine was approved by the European Medicines Agency (EMA) as a second-line therapy of metastatic and advanced urothelial cancer after failure of platinum-based treatment [A32626].
Betrixaban
go.drugbank.com/drugs/DB12364ApprovedIt was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity [A27286]. … VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients [A27287].
2-deoxyglucose
go.drugbank.com/drugs/DB08831InvestigationalAs an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).